Evidence map›Paper›PMID 30505658›Full record

ArticleActa pharmaceutica Sinica. B2018

High-throughput screening for small molecule inhibitors of the type-I interferon signaling pathway.

Elita Yuliantie, Xinchuan Dai, Dehua Yang, Peter J Crack, Ming-Wei Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Elita YuliantieThe National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Xinchuan DaiThe National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Dehua YangThe National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.
Peter J CrackDepartment of Pharmacology and Therapeutics, The University of Melbourne, Parkville, Victoria 3010, Australia.
Ming-Wei WangThe National Center for Drug Screening and the CAS Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences (CAS), Shanghai 201203, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferons (IFNs) are cytokines with fundamental roles in resistance to infections, cancer and other diseases. Type-I IFNs, interferon

Indexed as

cDNA, complementary DNACV, coefficient of variationDMEM, Dulbecco׳s modified Eagle׳s mediumDMSO, dimethyl sulfoxideFRET, fluorescence resonance energy transferHEK, human embryonic kidneyHigh-throughput screeningHTS, high-throughput screeningIFNAR, IFN alpha receptorIFN, interferonIFN regulatory factorInhibitorInterferon α receptorIRF, IFN regulatory factorISGF3, IFN-stimulated gene factor 3ISRE, IFN-stimulated response elementJAK, Janus activated kinaseJAK-STATpSTAT, phosphorylated STATS/B, signal to background ratioSEAP, secreted embryonic alkaline phosphataseSecreted embryonic alkaline phosphataseSTAT, signal transducer and activator of transcriptionTYK, tyrosine kinase

Identifiers

PMID30505658
PMCPMC6251811

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.